A study investigated the beneficial effects cilnidipine, in addition to renin-angiotensin system inhibitors, on ambulatory BP and heart rate (HR) profile, as well as cardiorenal function in hypertensive CKD patients. In all, 21 patients were randomly assigned to the cilnidipine replacement group and 24 to the control CCBs group over a 24-week active treatment period. Clinical BP values were similar in the cilnidipine and control CCBs groups following the treatment period. Ambulatory BP monitoring; however, showed that the 24-h and daytime systolic BP levels in the cilnidipine group were significantly lower compared with the control group. The left ventricular mass index (LVMI) was also significantly decreased in the cilnidipine group compared to the control group (LVMI, 135.3 ± 26.4 versus 181.2 ± 88.4). There was a significant difference in the changes in the LVMI between the cilnidipine and control groups (change in LVMI, -12.4 ± 23.7 versus 26.2 ± 64.4). Cilnidipine is thus effective for the suppression of pathological cardiac remodelling owing to a superior improving effect on ambulatory BP profile compared with control CCBs in hypertensive CKD patients. The findings were published in the International Journal of Molecular Sciences.